Arbutus Biopharma Corp Accounts Receivable
Arbutus Biopharma Corp (ABUS) had Accounts Receivable of $369.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Assets › Assets, Current › Receivables, Net, Current
us-gaap:AccountsReceivableNetCurrent · last filed 2026-08-12
- 2013-12-31: Accounts Receivable, after Allowance for Credit Loss, Current 116.56K CAD.
- 2012-12-31: Accounts Receivable, after Allowance for Credit Loss, Current 1.07M CAD; Accounts Receivable, after Allowance for Credit Loss, Current as first filed 1.07M CAD.
- 2011-12-31: Accounts Receivable, after Allowance for Credit Loss, Current 880.69K CAD.
- 2010-12-31: Accounts Receivable, after Allowance for Credit Loss, Current 3.32M CAD.
CAD
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current | Accounts Receivable, after Allowance for Credit Loss, Current as first filed |
|---|---|---|
| 2013-12-31 | 116.56K CAD 10-K · filed 2014-03-28 | |
| 2012-12-31 | 1.07M CAD 10-K · filed 2014-03-28 | 1.07M CAD 20-F · filed 2013-03-27 |
| 2011-12-31 | 880.69K CAD 20-F · filed 2013-03-27 | |
| 2010-12-31 | 3.32M CAD 20-F · filed 2012-03-27 |
USD
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current |
|---|---|
| 2026-06-30 | $369.00K 10-Q · filed 2026-08-12 |
| 2026-03-31 | $1.31M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $1.45M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $905.00K 10-Q · filed 2025-11-13 |
| 2025-06-30 | $1.02M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $1.18M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $2.41M 10-K · filed 2026-03-23 |
| 2024-09-30 | $1.61M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $1.77M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $2.14M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $1.78M 10-K · filed 2025-03-27 |
| 2023-09-30 | $2.17M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $2.61M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $2.66M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $1.35M 10-K · filed 2024-03-05 |
| 2022-09-30 | $1.83M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $1.97M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $1.31M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $899.00K 10-K · filed 2023-03-02 |
| 2021-09-30 | $1.67M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $1.30M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $1.26M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $1.31M 10-K · filed 2022-03-03 |
| 2020-09-30 | $1.07M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $1.11M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $1.07M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $1.20M 10-K · filed 2021-03-04 |
| 2019-09-30 | $2.49M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $1.53M 10-Q · filed 2019-08-05 |
| 2019-03-31 | $923.00K 10-Q · filed 2019-05-06 |
| 2018-12-31 | $1.43M 10-K · filed 2020-03-05 |
| 2018-09-30 | $538.00K 10-Q · filed 2018-11-07 |
| 2018-06-30 | $1.32M 10-Q · filed 2018-08-03 |
| 2018-03-31 | $719.00K 10-Q · filed 2018-05-04 |
| 2017-12-31 | $402.00K 10-K · filed 2019-03-07 |
| 2017-09-30 | $846.00K 10-Q · filed 2017-11-02 |
| 2017-06-30 | $1.04M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $7.88M 10-Q · filed 2017-05-04 |
| 2016-12-31 | $273.00K 10-K · filed 2018-03-16 |
| 2016-09-30 | $395.00K 10-Q · filed 2016-11-03 |
| 2016-06-30 | $456.00K 10-Q · filed 2016-08-04 |
| 2016-03-31 | $340.00K 10-Q · filed 2016-05-04 |
| 2015-12-31 | $1.01M 10-K · filed 2017-03-22 |
| 2015-09-30 | $2.19M 10-Q · filed 2015-11-05 |
| 2015-06-30 | $6.33M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $4.56M 10-Q · filed 2015-05-06 |
| 2014-12-31 | $1.90M 10-K · filed 2016-03-09 |
| 2014-09-30 | $2.09M 10-Q · filed 2014-11-07 |
| 2014-06-30 | $299.00K 10-Q · filed 2014-08-14 |
| 2014-03-31 | $1.52M 10-Q · filed 2014-05-14 |
| 2013-12-31 | $117.00K 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |